CA9 and renal cell adenocarcinoma: These factors support serial plasma-plus-urine sampling, RCC-specific surface targets such as CAIX or CD147, and tumor microenvironment (TME)-on-chip systems to contextualize biomarker function and drug response (116, 117, 144).